

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Sucampo Pharma Europe (lubiprostone) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Afiya Trust • Black Health Agency • Bladder and Bowel Foundation • Equalities National Council • Muslim Council of Britain • Muslim Health Network • Pain Concern • Pain Relief Foundation • Pain UK • PromoCon • South Asian Health Foundation • Specialised Healthcare Alliance • IBS Network <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Coloproctology of Great Britain and Ireland • Association for Continence Advice • Association for Palliative Medicine • British Geriatrics Society • British Pain Society • British Society of Gastroenterology • Primary Care Society for Gastroenterology • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Abbott Laboratories UK (lactulose) • Actavis UK (glycerol suppositories), • Amdipharm (methylcellulose) • Bell Sons & Co (Druggists) Limited (arachis oil) • Bio-Health (psyllium husk) • Boehringer Ingelheim UK (bisacodyl, docusate sodium, macrogol, sodium picosulphate) • B R Pharmaceuticals (senna) • Cardinal Health Martindale Products

National Institute for Health and Care Excellence

Matrix for the technology appraisal of lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain

Issue date: November 2013

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Richmond CCG • NHS North Staffordshire CCG • Welsh Government • NHS England 	<p>(glycerol suppositories, bisacodyl suppositories)</p> <ul style="list-style-type: none"> • Casen Fleet Laboratories (sodium dihydrogen phosphate dihydrate/disodium hydrogen phosphate dodecahydrate enema) • Chanelle Medical (bisacodyl, macrogol,) • Dr. Reddy's Laboratories UK (bisacodyl, macrogol) • Ecolab UK (arachis oil) • Forest Laboratories UK (arachis oil enema, , phosphates enema) • Hermal (ispaghula husk, glycerol suppositories, senna, Senokot direct relief suppositories) • Intrapharm Laboratories (lactulose) • J M Loveridge (arachis oil, methylcellulose) • LPC Medical UK (ispaghula husk) • Manx Healthcare (ispaghula husk) • Meda Pharmaceuticals (macrogol) • Napp Pharmaceuticals (dantron & naloxone-oxycodone) • Norgine Pharmaceuticals (sterculia/frangula, macrogol, docusate sodium enema) • Optima Consumer Health (arachis oil) • Perrigo (bisacodyl suppositories, dantron, sodium citrate enema, senna) • Pinewood Healthcare (sodium citrate enema, dantron) • Potter's Herbal Medicines UK (psyllium husk, senna) • Shire Pharmaceuticals (prucalopride) • Solvay Healthcare (lactulose) • Teva UK (glycerol suppositories, lactulose, , dantron, • Thornton & Ross (macrogol, magnesium hydroxide, glycerol suppositories, senna) • TMC Pharma (methylnaltrexone) • UCB Pharma (sodium citrate enema, docusate sodium)

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Zentiva UK (dantron,) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group • CORE (Digestive Disorders Foundation) • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People • Health Research Authority <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • NHS Centre for Reviews and Dissemination & Centre for Health Economics – York • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

STA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are:

manufacturers of comparator technologies;

Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.